Trials / Terminated
TerminatedNCT03694821
Knee Injection RCT
Efficacy and Cost-effectiveness of Intra-Articular Ketorolac Injection for Knee Osteoarthritis: A Randomized, Controlled, Double-Blinded Study
- Status
- Terminated
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- UConn Health · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Hypothesis: Ketorolac injection is a cost-effective adjunct in the nonoperative treatment of knee osteoarthritis (OA) compared to steroids and viscosupplementation. Aims/objectives: The objective of this randomized, controlled, double-blinded, prospective study is to assess the efficacy and cost-effectiveness of knee injection with ketorolac in the nonsurgical management of symptomatic OA compared to injections with corticosteroids and viscosupplements.
Detailed description
The purpose of this research study is to examine the effectiveness of intra-articular (inside the joint) ketorolac injection compared to injection with either corticosteroid or hyaluronic acid for the treatment of painful knee osteoarthritis. Patients will be randomly assigned to receive either ketorolac (a nonsteroidal anti-inflammatory drug, methylprednisolone (a steroid), hyaluronic acid (a substance that is naturally present in the human body).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ketorolac Tromethamine Injection | One knee injection of 2cc of ketorolac tromethamine (15mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine |
| DRUG | Methylprednisolone Acetate Injection | One knee injection of 2 cc of methylprednisolone acetate (40mg/cc) in 5cc of 0.5% ropivacaine hydrochloride without epinephrine |
| DRUG | Hylan G-F 20 | One knee injection of Hylan G-F 20 (Synvisc-One) |
Timeline
- Start date
- 2018-07-05
- Primary completion
- 2019-07-16
- Completion
- 2019-07-16
- First posted
- 2018-10-03
- Last updated
- 2020-02-18
- Results posted
- 2020-02-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03694821. Inclusion in this directory is not an endorsement.